Molecular & Cellular Toxicology

The Korean Society of Toxicogenomics and Toxicoproteomics (대한독성유전 단백체학회)
권호 표지

Protective Effect of Citrate against $A{\beta}$-induced Neurotoxicity in PC12 Cells

  • Yang, Hyun-Duk (Inam Neuroscience Research Center, Department of Neurology, Sanbon Medical Center, College of Medicine Wonkwang University) ;
  • Son, Il-Hong (Inam Neuroscience Research Center, Department of Neurology, Sanbon Medical Center, College of Medicine Wonkwang University) ;
  • Lee, Sung-Soo (Department of Neurology, Wonju Christian Hospital, Yonsei University Wonju College of Medicine) ;
  • Park, Yong-Hoon (Inam Neuroscience Research Center, Department of Neurology, Sanbon Medical Center, College of Medicine Wonkwang University)
  • Published : 2008.06.30
Download PDF
⟨ Previous Next ⟩

Abstract

Formation of ${\beta}$-amyloid $(A{\beta})$ fibrils has been identified as one of the major characteristics of Alzheimer's disease (AD). Inhibition of $A{\beta}$ fibril formation in the CNS would be attractive therapeutic targets for the treatment of AD. Several small compounds that inhibit amyloid formation or amyloid neurotoxicity in vitro have been known. Citrate has surfactant function effect because of its molecular structure having high anionic charge density, in addition to the well-known antibacterial and antioxidant properties. Therefore, we hypothesized that citrate might have the inhibitory effect against $A{\beta}$ fibril formation in vitro and have the protective effect against $A{\beta}$-induced neurotoxicity in PC12 cells. We examined the effect of citrate against the formation of $A{\beta}$ fibrils by measuring the intensity of fluorescence in thioflavin-T (Th-T) assay of between $A{\beta}_{25-35}$ groups treated with citrate and the control with $A{\beta}_{25-35}$ alone. The neuroprotective effect of citrate against $A{\beta}$-induced toxicity in PC12 cells was investigated using the WST-1 assay. Fluorescence spectroscopy showed that citrate inhibited dose-dependently the formation of $A{\beta}$ fibrils from ${\beta}$-amyloid peptides. The inhibition percentages of $A{\beta}$ fibril formation by citrate (1, 2.5, and 5 mM) were 31%, 60%, and 68% at 7 days, respectively in thioflavin-T (Th-T) assay. WST-1 assay revealed that the toxic effect of $A{\beta}_{25-35}$ was reduced, in a dose-dependent manner to citrate. The percentages of neuroprotection by citrate (1, 2.5, and 5 mM) against $A{\beta}-induced$ toxicity were 19%, 31 %, and 34%, respectively. We report that citrate inhibits the formation of $A{\beta}$ fibrils in vitro and has neuroprotective effect against $A{\beta}$-induced toxicity in PC12 cells. Neuroprotective effects of citrate against $A{\beta}$ might be, to some extent, attributable to its inhibition of $A{\beta}$ fibril formation. Although the mechanism of anti-amyloidogenic activity is not clear, the possible mechanism is that citrate might have two effects, salting-in and surfactant effects. These results suggest that citrate could be of potential therapeutic value in Alzheimer's disease.

Keywords

References

  1. Porat, Y., Abramowitz, A. & Gazit, E. Inhibition of amyloid fibril formation by polyphenols: structural similarity and aromatic interactions as a common inhibition mechanism. Chem Biol Drug Des 67:27-37 (2006) https://doi.org/10.1111/j.1747-0285.2005.00318.x
  2. Vetrivel, K. S. & Thinakaran, G. Amyloidogenic processing of ${\beta}$-amyloid precursor protein in intracellular compartments. Neurology 66:S69-S73 (2006) https://doi.org/10.1212/01.wnl.0000192393.05850.ec
  3. Selkoe, D. J. Alzheimer's disease: genes, proteins, and therapy. Physiol Rev 81:741-766 (2001) https://doi.org/10.1152/physrev.2001.81.2.741
  4. Sisodia, S. S. & St George-Hyslop, P. H. Gamma- Secretase, Notch, Abeta and Alzheimer's disease: where do the presenilins fit in? Nat Rev Neurosci 3:281-290 (2002) https://doi.org/10.1038/nrn785
  5. Pereira, C. et al. Alzheimer's disease-associated neurotoxic mechanisms and neuroprotective strategies. Curr Drug Targets CNS Neurol Disord 4:383-403 (2005). https://doi.org/10.2174/1568007054546117
  6. Selkoe, D. J. Translating cell biology into therapeutic advances in Alzheimer's disease. Nature 399:A23-A31 (1999) https://doi.org/10.1038/19866
  7. Yankner, B. A. Mechanisms of neuronal degeneration in Alzheimer's disease. Neuron 16:921-932 (1996) https://doi.org/10.1016/S0896-6273(00)80115-4
  8. Pike, C. J., Walencewicz, A. J., Glabe, C. G. & Cotman, C. W. In vitro aging of beta-amyloid protein causes peptide aggregation and neurotoxicity. Brain Res 563:311-314 (1991) https://doi.org/10.1016/0006-8993(91)91553-D
  9. Pike, C. J. et al. Neurodegeneration induced by betaamyloid peptides in vitro: the role of peptide assembly state. J Neurosci 13:1676-1687 (1993) https://doi.org/10.1523/JNEUROSCI.13-04-01676.1993
  10. Lorenzo, A. & Yankner, B. A. Beta-amyloid neurotoxicity requires fibril formation and is inhibited by Congo red. Proc Natl Acad Sci U S A 91:12243-12247 (1994)
  11. Citron, M. Strategies for disease modification in Alzheimer's disease. Nat Rev Neurosci 5:677-685 (2004) https://doi.org/10.1038/nrn1495
  12. Scarpini, E., Scheltens, P. & Feldman, H. Treatment of Alzheimer's disease: current status and new perspectives. Lancet Neurol 2:539-547 (2003) https://doi.org/10.1016/S1474-4422(03)00502-7
  13. Seiffert, D. et al. Presenilin-1 and -2 are molecular targets for gamma-secretase inhibitors. J Biol Chem 275:34086-34091 (2000) https://doi.org/10.1074/jbc.M005430200
  14. McConnell, S. & Riggs, J. Alzheimer's research: can it help save our nation's entitlement programs? Alzheimer Dementia 1:84-86 (2005) https://doi.org/10.1016/j.jalz.2005.06.005
  15. Cummings, J. L., Doody, R. & Clark, C. Disease-modifying therapies for Alzheimer disease: Challenges to early intervention. Neurology 69:1622-1634 (2007) https://doi.org/10.1212/01.wnl.0000295996.54210.69
  16. Kisilevsky, R. et al. Arresting amyloidosis in vivo using small-molecule anionic sulphonates or sulphates: implications for Alzheimer's disease. Nat Med 1:143-148 (1995) https://doi.org/10.1038/nm0295-143
  17. Allsop, D., Howlett, D., Christie, G. & Karran, E. Fibrillogenesis of beta-amyloid, Biochem Soc Trans 26: 459-463 (1998) https://doi.org/10.1042/bst0260459
  18. Pappolla, M. et al. Inhibition Alzheimer beta-fibrillogenesis by melatonin. J Biol Che 273: 7185-7188 (1998) https://doi.org/10.1074/jbc.273.13.7185
  19. Salomon, A. R., Marcinowski, K. J., Friedland, R. W. & Zagorski, M. G. Nicotine inhibits amyloid formation by the beta-peptide. Biochemistry 35:13568-13578 (1996) https://doi.org/10.1021/bi9617264
  20. Mook-Jung, I. et al. Estrogen blocks neurotoxic effects of beta-amyloid (1-42) and induces neurite extension in B103 cells. Neurosci Lett 235:101-104 (1997) https://doi.org/10.1016/S0304-3940(97)00632-0
  21. Merlini, G. et al. Interaction of the anthracycline 4'- iodo-4'-deoxydoxorubicin with amyloid fibrils: inhibition of amyloidogenesis. Proc Natl Acad Sci U S A 92:2959-2963 (1995)
  22. Soto, C., Kindy, M. S., Baumann, M. & Frangione, B. Inhibition of Alzheimer's amyloidosis by peptides that prevent beta-sheet conformation. Biochem Biophys Res Commun 226:672-680 (1996) https://doi.org/10.1006/bbrc.1996.1413
  23. Soto, C. et al. Beta-sheet breaker peptides inhibit fibrillogenesis in a rat brain model of amyloidosis: Implications for Alzheimer's therapy. Nat Med 4:822-826 (1998) https://doi.org/10.1038/nm0798-822
  24. Subramaniam, R. et al. The free radical antioxidant vitamin E protects cortical synaptosomal membranes from amyloid beta-peptide (25-35) toxicity but not from hydroxynonenal toxicity: relevance to the free radical hypothesis of Alzheimer's disease, Neurochem Res 23:1403-1410 (1998) https://doi.org/10.1023/A:1020754807671
  25. Goodman, Y., Steiner, M. R., Steiner, S. M. & Mattson, M. P. Nordihydroguaiaretic acid protects hippocampal neurons against amyloid beta-peptide toxicity, and attenuates free radical and calcium accumulation, Brain Res 654:171-176 (1994) https://doi.org/10.1016/0006-8993(94)91586-5
  26. Kihara, T. et al. Nicotinic receptor stimulation protects neurons against beta-amyloid toxicity, Ann Neurol 42:159-163 (1997) https://doi.org/10.1002/ana.410420205
  27. Ono, K. et al. Vitamin A exhibits potent antiamyloidogenic and fibril-destabilizing effects in vitro. Exp Neurol 189:380-392 (2004) https://doi.org/10.1016/j.expneurol.2004.05.035
  28. Ono, K., Hasegawa, K., Naiki, H. & Yamada, M. Preformed beta-amyloid fibrils are destabilized by coenzyme Q10 in vitro, Biochem Biophys Res Commun 330:111-116 (2005) https://doi.org/10.1016/j.bbrc.2005.02.132
  29. Lomakin, A. et al. On the nucleation and growth of amyloid beta-protein fibrils: Detection of nuclei and quantitation of rate constants. Proc Natl Acad Sci U S A 93:1125-1129 (1996)
  30. Lin, S. J., Shiao, Y. J., Chi, C. W. & Yang, L. M. Abeta aggregation inhibitors: Part 1. Synthesis and biological activity of phenylazo benzenesulfonamides. Bioorg Med Chem Lett 14:1173-1176 (2004) https://doi.org/10.1016/j.bmcl.2003.12.086
  31. Marcinowski, K. J., Shao, H., Clancy, E. L. & Zagorski, M. G. Solution structure model of residues 1-28 of the amyloid beta peptide when bound to micelles. J Am Chem Soc 120:11082-11091 (1998) https://doi.org/10.1021/ja9738687
  32. Wang, S. S., Chen, Y. T. & Chou, S. W. Inhibition of amyloid fibril formation of beta-amyloid peptides via the amphiphilic surfactants. Biochim Biophys Acta 1741:307-313 (2005) https://doi.org/10.1016/j.bbadis.2005.05.004
  33. Wood, S. J. et al. Selective inhibition of Abeta fibril formation. J Biol Chem 271:4086-4092 (1996) https://doi.org/10.1074/jbc.271.8.4086
  34. Pike, C. J. et al. Structure-activity analyses of betaamyloid peptides: contributions of the beta 25-35 region to aggregation and neurotoxicity. J Neurochem 64:253-265 (1995) https://doi.org/10.1046/j.1471-4159.1995.64010253.x
  35. Riviere, C. et al. Inhibitory activity of stilbenes on Alzheimer's beta-amyloid fibrils in vitro. Bioorg Med Chem 15:1160-1167 (2007) https://doi.org/10.1016/j.bmc.2006.09.069
  36. Hilbich, C. et al. Substitutions of hydrophobic amino acids reduce the amyloidogenicity of Alzheimer's disease beta A4 peptides. J Mol Biol 228:460-473 (1992) https://doi.org/10.1016/0022-2836(92)90835-8
  37. Barrow, C. J., Yasuda, A., Kenny, P. T. & Zagorski, M. G. Solution conformations and aggregational properties of synthetic amyloid beta-peptides of Alzheimer's disease. Analysis of circular dichroism spectra, J Mol Biol 225:1075-1093 (1992) https://doi.org/10.1016/0022-2836(92)90106-T
  38. Soto, C., Castano, E. M., Frangione, B. & Inestrosa, N. C. The alpha-helical to beta-strand transition in the amino-terminal fragment of the amyloid beta-peptide modulates amyloid formation. J Biol Chem 270:3063-3067 (1995) https://doi.org/10.1074/jbc.270.7.3063
  39. Soto, C. & Castano, E. M. The conformation of Alzheimer's beta peptide determines the rate of amyloid formation and its resistance to proteolysis. Biochem J 314:701-707 (1996) https://doi.org/10.1042/bj3140701
  40. Ghanta, J., Shen, C. L., Kiessling, L. L. & Murphy, R. M. A strategy for designing inhibitors of beta-amyloid toxicity. J Biol Chem 271:29525-29528 (1996) https://doi.org/10.1074/jbc.271.47.29525
  41. Pallitto, M. M. et al. Recognition sequence design for peptidyl modulators of beta-amyloid aggregation and toxicity. Biochemistry 38:3570-3578 (1999) https://doi.org/10.1021/bi982119e
  42. Findeis, M. A. et al. Modified-peptide inhibitors of amyloid beta-peptide polymerization. Biochemistry 38:6791-6800 (1999) https://doi.org/10.1021/bi982824n
  43. Findeis, M. A. et al. Characterization of cholyl-leuval- phe-phe-ala-OH as an inhibitor of amyloid betapeptide polymerization. Amyloid 8:231-241 (2001) https://doi.org/10.3109/13506120108993819
  44. McWilliam Leitch, E. C. & Stewart, C. S. Susceptibility of Escherichia coli O157 and non-O157 isolates to lactate. Lett Appl Microbiol 35:176-180 (2002) https://doi.org/10.1046/j.1472-765X.2002.01164.x
  45. Sallam, K. I. Antimicrobial and antioxidant effects of sodium acetate, sodium lactate, and sodium citrate in refrigerated sliced salmon. Food Control 18:566-575 (2007) https://doi.org/10.1016/j.foodcont.2006.02.002
  46. Puntel, R. L. et al. Antioxidant properties of Krebs cycle intermediates against malonate pro-oxidant activity in vitro: a comparative study using the colorimetric method and HPLC analysis to determine malondialdehyde in rat brain homogenates. Life Sci 81:51-62 (2007) https://doi.org/10.1016/j.lfs.2007.04.023
  47. Yonekawa, C., Nakae, H., Tajimi, K. & Asanuma, Y. Effectiveness of combining plasma exchange and continuous hemodiafiltration in patients with postoperative liver failure. Artificial Organs 29:324-328 (2005) https://doi.org/10.1111/j.1525-1594.2005.29054.x
  48. Hofmeister, F. Zur Lehre von der Wirkung der Salze. [Title translation: About the science of the effect of salts.] Arch Exp Pathol Pharmakol 24:247-260 (1888) https://doi.org/10.1007/BF01918191
  49. Zhang, Y. & Cremer, P. S. Interactions between macromolecules and ions: The Hofmeister series. Curr Opin Chem Biol 10:658-663 (2006) https://doi.org/10.1016/j.cbpa.2006.09.020
  50. Ishiyama, M. et al. A combined assay of cell viability and in vitro cytotoxicity with a highly water-soluble tetrazolium salt, neutral red and crystal violet. Biol Pharm Bull 19:1518-1520 (1996) https://doi.org/10.1248/bpb.19.1518